We present a review of critical concepts and produce recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition, first ...

Myeloproliferative neoplasms (MPNs) disrupt the normal hematopoietic process. MPNs cause excess red blood cells, white blood cells, or platelets to be formed, which can then lead to fibrosis, ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Patients with Philadelphia chromosome-negative accelerated- or blast-phase myeloproliferative ...

Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers in which the bone marrow produces an excess combination of white blood cells, red blood cells, and platelets. This overproduction ...

Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article.

IFN-α2 (in most centers today pegylated IFN-α2 [Peg-IFN-α2]) induces major or complete molecular remissions in a subset of JAK2V617-positive patients with essential thrombocythemia (ET) and ...

Key opinion leaders highlight different testing and workup methods involved in making an accurate diagnosis of myeloproliferative neoplasms. Ruben Mesa, M.D.: Rami (Rami Komrokji, M.D.), how would you ...

—In a new study, revascularization reduced major adverse cardiovascular and limb events (MACLE) and amputations, but it increased bleeding and stroke risk, highlighting the need for careful risk ...

Ruben Mesa, M.D.,Rami S. Komrokji, M.D. Experts Rami Komrokji, MD, and Ruben Mesa, MD, define myeloproliferative neoplasms (MPNs) and explain differences between ...

Inflammation and genetic mutations can drive cardiovascular complications in patients with myeloproliferative neoplasms, which include disorders such as polycythemia vera, essential thrombocythemia, ...